HRP20161530T1 - 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori - Google Patents

2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori Download PDF

Info

Publication number
HRP20161530T1
HRP20161530T1 HRP20161530TT HRP20161530T HRP20161530T1 HR P20161530 T1 HRP20161530 T1 HR P20161530T1 HR P20161530T T HRP20161530T T HR P20161530TT HR P20161530 T HRP20161530 T HR P20161530T HR P20161530 T1 HRP20161530 T1 HR P20161530T1
Authority
HR
Croatia
Prior art keywords
pyrrolo
pyridin
methanone
benzo
methyl
Prior art date
Application number
HRP20161530TT
Other languages
English (en)
Croatian (hr)
Inventor
Stephen John Atkinson
Michael David Barker
Matthew Campbell
Hawa Diallo
Clement Douault
Neil Stuart Garton
John Liddle
Robert John Sheppard
Ann Louis Walker
Christopher WELLAWAY
David Matthew Wilson
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HRP20161530T1 publication Critical patent/HRP20161530T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20161530TT 2012-07-26 2012-07-26 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori HRP20161530T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12740581.9A EP2877467B1 (en) 2012-07-26 2012-07-26 2-(azaindol-2-yl)benzimidazoles as pad4 inhibitors
PCT/EP2012/064649 WO2014015905A1 (en) 2012-07-26 2012-07-26 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors

Publications (1)

Publication Number Publication Date
HRP20161530T1 true HRP20161530T1 (hr) 2017-02-10

Family

ID=49996626

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161530TT HRP20161530T1 (hr) 2012-07-26 2012-07-26 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori

Country Status (22)

Country Link
US (4) US9127003B2 (enExample)
EP (1) EP2877467B1 (enExample)
JP (1) JP6063567B2 (enExample)
KR (1) KR101916443B1 (enExample)
CN (1) CN104470919B (enExample)
AU (1) AU2012386257B2 (enExample)
BR (1) BR112015001545B1 (enExample)
CA (1) CA2879341C (enExample)
CY (1) CY1118524T1 (enExample)
DK (1) DK2877467T3 (enExample)
ES (1) ES2609126T3 (enExample)
HR (1) HRP20161530T1 (enExample)
HU (1) HUE033294T2 (enExample)
IN (1) IN2014KN02935A (enExample)
LT (1) LT2877467T (enExample)
PL (1) PL2877467T3 (enExample)
PT (1) PT2877467T (enExample)
RS (1) RS55684B1 (enExample)
RU (1) RU2611010C2 (enExample)
SI (1) SI2877467T1 (enExample)
SM (2) SMT201700052T1 (enExample)
WO (1) WO2014015905A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986199C (en) * 2015-05-21 2023-07-18 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as pad4 inhibitors
AR107030A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
AR107694A1 (es) 2016-02-23 2018-05-23 Padlock Therapeutics Inc Heteroarilos inhibidores de pad4
CN107188867A (zh) * 2016-03-14 2017-09-22 中国科学院天津工业生物技术研究所 精氨酸脱亚氨酶4的抑制剂
WO2018022897A1 (en) * 2016-07-27 2018-02-01 Padlock Therapeutics, Inc. Covalent inhibitors of pad4
CN110248934B (zh) * 2016-09-12 2022-05-24 帕德罗科治疗公司 杂芳基pad4抑制剂
WO2018102262A1 (en) * 2016-12-02 2018-06-07 University Of Massachusetts Inhibitors of protein arginine deiminases (pads) and methods of preparation and use thereof
CN108689946B (zh) * 2017-04-12 2022-10-18 中国科学院上海药物研究所 2-取代硫基乙酰胺类化合物及其制备方法和应用
SG11202002032SA (en) * 2017-09-22 2020-04-29 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
CA3076476A1 (en) * 2017-10-18 2019-04-25 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
PL3704120T3 (pl) 2017-11-24 2024-09-16 Jubilant Episcribe Llc Związki heterocykliczne jako inhibitory prmt5
WO2019161803A1 (zh) 2018-02-26 2019-08-29 南京药捷安康生物科技有限公司 肽酰精氨酸脱亚胺酶抑制剂及其用途
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
JP7447080B2 (ja) 2018-08-08 2024-03-11 ブリストル-マイヤーズ スクイブ カンパニー Pad4阻害剤としての置換チエノピロール
US20220402950A1 (en) * 2018-08-08 2022-12-22 Bristol-Myers Squibb Company Substituted benzimidazoles as pad4 inhibitors
EP3833439B1 (en) * 2018-08-08 2023-07-12 Bristol-Myers Squibb Company Benzimidazole inhibitors of pad enzymes
AU2019319835A1 (en) * 2018-08-08 2021-03-25 Bristol-Myers Squibb Company Indole and azaindole inhibitors of PAD enzymes
CN109369513B (zh) * 2018-11-20 2020-08-25 都创(上海)医药科技有限公司 一种fbdd常用分子片段的制备方法
CN113164508B (zh) 2018-12-19 2025-07-08 达萨玛治疗公司 与神经保护剂组合的sarm1抑制剂
EP3994128A4 (en) * 2019-07-03 2022-12-07 University of Massachusetts INHIBITORS OF PROTEIN ARGININE DEIMINASE 1, AND PROCESSES FOR THEIR PREPARATION AND USE
WO2021057910A1 (zh) * 2019-09-27 2021-04-01 南京药捷安康生物科技有限公司 肽酰精氨酸脱亚胺酶抑制剂及其用途
KR20220137694A (ko) 2020-02-06 2022-10-12 브리스톨-마이어스 스큅 컴퍼니 면역억제제로서 유용한 마크로시클릭 pad4 억제제
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
CN111265526B (zh) * 2020-04-09 2021-03-19 黑龙江中医药大学 一种治疗胃癌的药物及其制备方法
CN115551862B (zh) 2020-04-30 2024-04-12 吉利德科学公司 肽基精氨酸脱亚胺酶的大环抑制剂
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
US20230365589A1 (en) 2020-09-18 2023-11-16 Sumitomo Pharma Co., Ltd. Novel amine derivatives
EP4267562A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
EP4267587A2 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
WO2023083365A1 (en) 2021-11-15 2023-05-19 Qilu Regor Therapeutics Inc. Pad4 inhibitors and use thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
KR20250027599A (ko) * 2022-05-26 2025-02-26 셀진 코포레이션 헤테로시클릭 pad4 억제제
JP2025537627A (ja) * 2022-11-24 2025-11-19 ヘリオス ファミン バイオファーマ カンパニー リミテッド セレン含有複素環式化合物およびその使用
KR20260041867A (ko) 2023-07-21 2026-03-27 브리스톨-마이어스 스큅 컴퍼니 Pad4 조정제의 시트룰린화 및 활성을 평가하는 방법
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
SI0820279T1 (en) 1995-04-14 2002-12-31 Smithkline Beecham Corporation Metered dose inhaler for albuterol
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
HK1039325B (en) * 1998-09-18 2006-02-24 Abbott Gmbh & Co. Kg 4-aminopyrrolopyrimidines as kinase inhibitors
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
JP2003512353A (ja) * 1999-10-19 2003-04-02 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
EP1990343B1 (en) 1999-12-24 2012-04-04 Aventis Pharma Limited Azaindoles
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
CN1901958B (zh) 2003-11-03 2011-03-09 葛兰素集团有限公司 流体分配装置
JP2007511596A (ja) 2003-11-17 2007-05-10 ファイザー・プロダクツ・インク 癌の治療において有用なピロロピリミジン化合物
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7429611B2 (en) 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
US20100197657A1 (en) 2007-09-25 2010-08-05 Chang Ronald K 2-aryl or heteroaryl indole derivatives
WO2009155042A1 (en) 2008-05-28 2009-12-23 Wyeth 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
RU2011106786A (ru) * 2008-07-23 2012-08-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы пиразолопиридинкиназы
SG174125A1 (en) * 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
US20100305093A1 (en) 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using

Also Published As

Publication number Publication date
CY1118524T1 (el) 2017-07-12
RS55684B1 (sr) 2017-07-31
CA2879341C (en) 2019-06-11
US10039755B2 (en) 2018-08-07
RU2014152456A (ru) 2016-09-20
US20180161316A1 (en) 2018-06-14
KR101916443B1 (ko) 2018-11-08
RU2611010C2 (ru) 2017-02-17
WO2014015905A1 (en) 2014-01-30
AU2012386257B2 (en) 2016-09-08
BR112015001545A2 (pt) 2017-07-04
US9127003B2 (en) 2015-09-08
EP2877467B1 (en) 2016-11-02
US20150175600A1 (en) 2015-06-25
AU2012386257A1 (en) 2015-03-12
SI2877467T1 (sl) 2017-02-28
US20170119750A1 (en) 2017-05-04
US9833449B2 (en) 2017-12-05
CN104470919A (zh) 2015-03-25
SMT201700052B (it) 2017-03-08
PT2877467T (pt) 2017-01-02
IN2014KN02935A (enExample) 2015-05-08
LT2877467T (lt) 2017-01-10
HUE033294T2 (en) 2017-11-28
CA2879341A1 (en) 2014-01-30
US20160009716A1 (en) 2016-01-14
CN104470919B (zh) 2016-07-06
JP2015522628A (ja) 2015-08-06
BR112015001545B1 (pt) 2022-07-05
EP2877467A1 (en) 2015-06-03
ES2609126T3 (es) 2017-04-18
US9518054B2 (en) 2016-12-13
DK2877467T3 (en) 2017-02-13
KR20150038438A (ko) 2015-04-08
SMT201700052T1 (it) 2017-03-08
JP6063567B2 (ja) 2017-01-18
PL2877467T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
RU2014152456A (ru) 2-(азаиндол-2-ил)бензимидазолы в качестве ингибиторов PAD4
FIC20200051I1 (fi) Entrektinibi tai sen tautomeerit tai farmaseuttisesti hyväksyttävät suolat
MX2010005824A (es) Derivados de aminotiazol.
WO2008046758A3 (en) Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
ZA201108373B (en) 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
IL212250A0 (en) Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition
EP2017263A4 (en) Heteroarylamide derivative of a lower carboxylic acid
IN2012DN03337A (enExample)
EP2771492A4 (en) SCALABLE PROCESS FOR THE MANUFACTURE OF TIN NANOPARTICLES, COMPOSITIONS WITH TIN NANOPARTICLES AND APPLICATIONS THEREWITH
FR2951885B1 (fr) Dispositif d'amplification multi-ports compense en presence de trafic
EP2648697A4 (en) METHOD FOR THE PRODUCTION OF MINIEMULSIONS AND USE FOR THE RELEASE OF BIOACTIVE ACTIVE SUBSTANCES
ZA201200585B (en) "indole derivative and pharmaceutically acceptable salt thereof"
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
MX2007008141A (es) Composicion farmaceutica de sustancias labiles en medio acido.
EP2137091B1 (fr) Dispositif d'orientation de preformes
FR2940116B1 (fr) Formulation pour l'administration d'hypolipemiant par voie trans-muqueuse buccale
ZA200902575B (en) Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof
TW200740764A (en) Pyrazolone derivatives
MX2011011716A (es) Derivados de isoquinolina novedosos.
MX2013002694A (es) Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina.
EP2440192A4 (en) COMPOSITIONS AND PROCESSES FOR MATERIAL DELIVERY
EP2239797A4 (en) FULL DERIVATIVE COMPOSITION AND THOSE USING ORGANIC PHOTOELECTRIC TRANSDUCERS
FR2940120B1 (fr) Formulation pour l'administration par voie trans-muqueuse de setrons
IL195426A0 (en) Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor
EP2271469A4 (en) FORM AND FORMNEST FOR PREPARATION